Skip to content
10-Q

Quarterly Report

Definium Therapeutics, Inc. DFTX

0001193125-26-211989

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 109.07M sh
Shares Diluted Q1 2026 · Mar 31, 2026 108.79M sh
Shares Diluted Q1 2026 · Mar 31, 2025 87.09M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$42.63M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$29.42M
Long Term Debt Q1 2026 · Mar 31, 2026 $40.77M
Short Term Investments Q1 2026 · Mar 31, 2026 $110.9M
Short Term Investments Q1 2026 · Dec 31, 2025 $153.76M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $262.52M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $257.84M
Stockholders Equity Q1 2026 · Mar 31, 2026 $278.85M
Stockholders Equity Q1 2026 · Dec 31, 2025 $332.33M
Stockholders Equity Q1 2026 · Mar 31, 2025 $222.81M
Stockholders Equity Q1 2026 · Dec 31, 2024 $241.45M
Current Liabilities Q1 2026 · Mar 31, 2026 $81.11M
Current Liabilities Q1 2026 · Dec 31, 2025 $66.7M
Total Liabilities Q1 2026 · Mar 31, 2026 $122.44M
Total Liabilities Q1 2026 · Dec 31, 2025 $107.77M
Current Assets Q1 2026 · Mar 31, 2026 $380.56M
Current Assets Q1 2026 · Dec 31, 2025 $419.32M
Total Assets Q1 2026 · Mar 31, 2026 $401.29M
Total Assets Q1 2026 · Dec 31, 2025 $440.1M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.71
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.35
Eps Basic Q1 2026 · Mar 31, 2026 −$0.71
Eps Basic Q1 2026 · Mar 31, 2025 −$0.27
Sga Expense Q1 2026 · Mar 31, 2026 $17.74M
Sga Expense Q1 2026 · Mar 31, 2025 $8.8M
Rd Expense Q1 2026 · Mar 31, 2026 $41.48M
Rd Expense Q1 2026 · Mar 31, 2025 $23.36M
Net Income Q1 2026 · Mar 31, 2026 −$77.1M
Net Income Q1 2026 · Mar 31, 2025 −$23.35M
Operating Income Q1 2026 · Mar 31, 2026 −$59.22M
Operating Income Q1 2026 · Mar 31, 2025 −$32.16M